C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $250 | $280 | $288 | $1,483 |
| - Cash | $55 | $127 | $30 | $76 |
| + Debt | $66 | $71 | $87 | $43 |
| Enterprise Value | $260 | $225 | $346 | $1,449 |
| Revenue | $36 | $21 | $31 | $46 |
| % Growth | 71.4% | -33.3% | -32.1% | – |
| Gross Profit | $36 | $13 | $31 | $46 |
| % Margin | 100% | 62.7% | 100% | 100% |
| EBITDA | -$103 | -$122 | -$124 | -$80 |
| % Margin | -290.5% | -588.3% | -399.7% | -175.3% |
| Net Income | -$105 | -$132 | -$128 | -$84 |
| % Margin | -296% | -638.3% | -412.2% | -183.2% |
| EPS Diluted | -1.52 | -2.67 | -2.62 | -1.82 |
| % Growth | 43.1% | -1.9% | -44% | – |
| Operating Cash Flow | -$65 | -$107 | -$106 | -$87 |
| Capital Expenditures | -$0 | -$2 | -$5 | -$1 |
| Free Cash Flow | -$65 | -$109 | -$111 | -$88 |